Exploration of LPS2 agonist binding modes using the combination of a new hydrophobic scaffold and homology modeling.

Lysophosphatidylserine (LysoPS) is an endogenous pan-agonist of three G-protein coupled receptors (GPCRs): LPS 1 /GPR34, LPS 2 /P2Y 10 , and LPS 3 /GPR174, and we previously reported a series of LysoPS-based agonists of these receptors. Interestingly, we found that LPS 1 agonist activity was very sensitive to structural change at the hydrophobic fatty acid moiety, whereas LPS 2 agonist activity was not. Here, to probe the molecular basis of LPS 2 agonist binding, we developed a new class of hydrophobic fatty acid surrogates having a biphenyl-ether scaffold. The LPS 2 agonist activity of these compounds proved sensitive to molecular modification of the hydrophobic skeleton. Thus, we next constructed an LPS 2 model by homology modeling and docking/molecular dynamics (MD) simulation, and validated it by means of SAR studies together with point mutations of selected receptor amino-acid residues. The putative ligand-binding site of LPS 2 is Γ-shaped, with a hydrophilic site horizontally embedded in the receptor transmembrane helix bundles and a perpendicular hydrophobic groove adjoining transmembrane domains 4 and 5 that is open to the membrane bilayer. The binding poses of LPS 2 agonists to this site are consistent with easy incorporation of various kinds of fatty acid surrogates. Structural development based on this model afforded a series of potent and selective LPS 2 full agonists, which showed enhanced in vitro actin stress fiber formation effect. [Display omitted] • A biphenyl-ether skeleton of LPS 2 -selective agonist was found to amplify the activity change upon structural modifications of the hydrophobic moiety. • Docking studies and point mutation of the receptor elucidated LPS 2 agonist binding mode as representing a hydrophilic site parallel to membrane bilayer and a perpendicular hydrophobic groove between transmembrane helices 4 & 5. • Binding model-guided-ligand design led to the development of potent and selective LPS 2 agonists with improved actin stress fiber formation activity. [ABSTRACT FROM AUTHOR]